Exendin-9,39 and Satiety After Bariatric Surgery

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2019

Conditions
Obesity
Interventions
DRUG

Saline

Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.

DRUG

Exendin-9,39

Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The Obesity Society

OTHER

lead

Mayo Clinic

OTHER